SPECIALIZED PRESS September 15, 2020 Not intended for U.S. and UK MediaBayer and Systems Oncology sign exclusive license agreement on innovative breast cancer treatment approach ERSO™ Read more
September 10, 2020 Bayer: Supervisory Board extends CEO Werner Baumann’s contract until the end of April 2024Read more
SPECIALIZED PRESS September 9, 2020 Not intended for U.S. and UK MediaNew England Journal of Medicine publishes final overall survival data for Nubeqa™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancerRead more
September 9, 2020 Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseasesRead more
SPECIALIZED PRESS September 9, 2020 Not intended for U.S. and UK MediaBayer completes acquisition of UK-based biotech company KaNDy Therapeutics Ltd.Read more
SPECIALIZED PRESS September 8, 2020 Not intended for U.S. and UK MediaBayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Read more
SPECIALIZED PRESS August 28, 2020 Not intended for U.S. and UK MediaBayer submits vericiguat for marketing authorization in China for the treatment of chronic heart failureRead more
August 27, 2020 Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira ImmunologicsRead more
SPECIALIZED PRESS August 27, 2020 Not intended for U.S. and UK MediaBayer receives approval for Xofigo® in ChinaRead more
August 24, 2020 Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areasRead more
